Open AccessA phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
Author(s) -
Pooler Darcy B.,
Ness Dylan B.,
Danilov Alexey V.,
Labrie Bridget M.,
Tosteson Tor D.,
Eastman Alan,
Lewis Lionel D.,
Lansigan Frederick
Publication year - 2022
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.543
Subject(s) - ibrutinib , chronic lymphocytic leukemia , bruton's tyrosine kinase , medicine , idelalisib , lymphocytosis , tumor lysis syndrome , cancer research , oncology , venetoclax , chemoimmunotherapy , leukemia , immunology , tyrosine kinase , chemotherapy , receptor
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom